To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
(-)-18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine and nicotine. 18MC is a selective α3β4 nicotinic antagonist and, opposed to ibogaine, has no affinity at the α4β2 subtype nor at NMDA-channels nor at the serotonin transporter. 18-MC has not yet been tested in humans. In 2002 the research team started trying to raise funds for human trials, but were unable to secure the estimated $5 million needed. Efforts to raise funds for future trials are still ongoing.
Additional recommended knowledge
Its CAS number is [308123-60-6] for the free base and [266686-77-5] for the monohydrochloride.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "18-Methoxycoronaridine". A list of authors is available in Wikipedia.|